These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8002633)

  • 1. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
    Ishida R; Andoh T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
    Liu LF; D'Arpa P
    Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
    [No Abstract]   [Full Text] [Related]  

  • 3. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerases and topoisomerase inhibitors.
    Giaccone G
    Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DNA topoisomerases and resistance to anticancer agents].
    Andoh T; Okada K
    Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 2):569-75. PubMed ID: 2539786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
    Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
    Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
    Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
    Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
    Holden JA
    Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BN80927: a novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo.
    Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Camara J; Kasprzyk PG; Prévost G; Bigg DC
    Cancer Res; 2004 Jul; 64(14):4942-9. PubMed ID: 15256467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.
    Eng WK; Faucette L; Johnson RK; Sternglanz R
    Mol Pharmacol; 1988 Dec; 34(6):755-60. PubMed ID: 2849043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
    Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
    Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
    Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
    Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
    Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
    Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.